Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer

M. Z. Berger; M. G. Kris; R. J. Gralla; L. D. Marks; L. M. Potanovich; J. J. Dimaggio; R. T. Heelan

doi:10.1097/00000421-199104000-00006

Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer

M. Z. Berger, M. G. Kris, R. J. Gralla, L. D. Marks, L. M. Potanovich, J. J. Dimaggio, R. T. Heelan

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Amonafide (benzisoquinolinedione, nafidimide, NSC 308847) is an anticancer agent that functions as a DNA intercalator. Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m² i.v. daily for 5 days every 21 days. No major objective responses were observed among the 14 patients adequately treated (95% confidence limits 0-20%). Local reactions at the injection site or phlebitis were seen in 14 of the 16 patients. Leukopenia (44%), nausea or vomiting (38%), and thrombocytopenia and rash (each 25%) were also noted. With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer.

Original language	English (US)
Pages (from-to)	124-126
Number of pages	3
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	14
Issue number	2
DOIs	https://doi.org/10.1097/00000421-199104000-00006
State	Published - 1991
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00000421-199104000-00006

Cite this

@article{1497e8c79afd41e285efc5724fe61cb0,

title = "Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer",

abstract = "Amonafide (benzisoquinolinedione, nafidimide, NSC 308847) is an anticancer agent that functions as a DNA intercalator. Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. No major objective responses were observed among the 14 patients adequately treated (95% confidence limits 0-20%). Local reactions at the injection site or phlebitis were seen in 14 of the 16 patients. Leukopenia (44%), nausea or vomiting (38%), and thrombocytopenia and rash (each 25%) were also noted. With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer.",

author = "Berger, {M. Z.} and Kris, {M. G.} and Gralla, {R. J.} and Marks, {L. D.} and Potanovich, {L. M.} and Dimaggio, {J. J.} and Heelan, {R. T.}",

year = "1991",

doi = "10.1097/00000421-199104000-00006",

language = "English (US)",

volume = "14",

pages = "124--126",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer

AU - Berger, M. Z.

AU - Kris, M. G.

AU - Gralla, R. J.

AU - Marks, L. D.

AU - Potanovich, L. M.

AU - Dimaggio, J. J.

AU - Heelan, R. T.

PY - 1991

Y1 - 1991

N2 - Amonafide (benzisoquinolinedione, nafidimide, NSC 308847) is an anticancer agent that functions as a DNA intercalator. Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. No major objective responses were observed among the 14 patients adequately treated (95% confidence limits 0-20%). Local reactions at the injection site or phlebitis were seen in 14 of the 16 patients. Leukopenia (44%), nausea or vomiting (38%), and thrombocytopenia and rash (each 25%) were also noted. With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer.

AB - Amonafide (benzisoquinolinedione, nafidimide, NSC 308847) is an anticancer agent that functions as a DNA intercalator. Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. No major objective responses were observed among the 14 patients adequately treated (95% confidence limits 0-20%). Local reactions at the injection site or phlebitis were seen in 14 of the 16 patients. Leukopenia (44%), nausea or vomiting (38%), and thrombocytopenia and rash (each 25%) were also noted. With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025805839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025805839&partnerID=8YFLogxK

U2 - 10.1097/00000421-199104000-00006

DO - 10.1097/00000421-199104000-00006

M3 - Article

C2 - 1851387

AN - SCOPUS:0025805839

SN - 0277-3732

VL - 14

SP - 124

EP - 126

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 2

ER -

Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this